ARS 02
Alternative Names: ARS-02Latest Information Update: 10 Dec 2025
At a glance
- Originator ARScience Bio
- Class Interleukins
- Mechanism of Action Interleukin 2 modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Neurodegenerative disorders
Most Recent Events
- 22 Jul 2025 Preclinical trials in Neurodegenerative disorders (Monotherapy) in USA (unspecified route), Prior to July 2025 (ARScience Bio pipeline, July 2025)